CNS Pharmaceuticals, Inc. — Q2 2022 Form 10-Q
Business context and reporting period. This clinical-stage pharmaceutical company develops anticancer candidates for brain and central nervous system tumors. The unaudited filing covers the quarter and six months ended June 30, 2022. Its lead candidate, Berubicin, was in a Phase II trial for glioblastoma; the company reported no product revenue.
Financial results and position
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Operating expenses | $3.56 million in 2022; $3.81 million in 2021 | $6.35 million in 2022; $7.42 million in 2021 |
| Research and development | $2.22 million in 2022; $2.66 million in 2021 | $3.74 million in 2022; $4.87 million in 2021 |
| General and administrative | $1.34 million in 2022; $1.15 million in 2021 | $2.60 million in 2022; $2.55 million in 2021 |
| Net loss | $3.57 million in 2022; $3.81 million in 2021 | $6.35 million in 2022; $7.43 million in 2021 |
| Basic and diluted loss per share | $0.09 in 2022; $0.15 in 2021 | $0.16 in 2022; $0.30 in 2021 |
- Cash and cash equivalents were $8.96 million at June 30, 2022, versus $5.00 million at December 31, 2021. Working capital was approximately $10.47 million.
- Six-month operating cash use was $6.44 million, compared with $8.31 million in 2021; investing cash use was $2,909. Financing provided $10.40 million, primarily from the January equity financing.
- Current liabilities were $923,856, including $156,397 of notes payable, down from $2.14 million of current liabilities and $387,794 of notes payable at year-end. The short-term note bears 3.3% interest and was due to be fully repaid by September 30, 2022.
- There is no meaningful operating margin to report because the company had no revenue and reported operating losses. Total assets were $12.45 million and stockholders’ equity was $11.52 million at June 30.
Changes, outlook, and material risks
- Six-month net loss narrowed by about $1.08 million year over year, mainly as research and development costs fell by about $1.13 million. Management attributed the decline to lower manufacturing activity and a credit for funds collected from WPD Pharmaceuticals, partly offset by higher clinical-trial organization costs. G&A rose modestly for the six-month period, including higher legal and professional fees.
- In January, the company raised approximately $11.5 million gross and $10.63 million net through common shares, pre-funded warrants, and warrants. Common shares outstanding rose from 27.93 million at year-end to 40.03 million at June 30. The offering and warrant structure create potential dilution.
- Management estimated that it would need an additional $13–$17 million to complete the Berubicin Phase II trial, about $5 million for near-term WP1244/WP1874 preclinical work, and additional working capital. It expected current cash to fund operations into, but not beyond, the first quarter of 2023; trial timing and cost estimates may change.
- The filing states that recurring losses and operating cash outflows raise substantial doubt about the company’s ability to continue as a going concern. Management said continued operations depend on obtaining financing; additional funding may not be available on acceptable terms or at all.
- The Berubicin Phase II study compares the drug with Lomustine, uses overall survival as its primary endpoint, and was planned to enroll approximately 243 patients. The filing cautions that trial success, regulatory approval, commercialization, and patient acceptance are uncertain. The company relies on third parties for manufacturing and has no sales organization.
- Nasdaq had notified the company that its bid price was below the $1 minimum. The initial compliance period ended August 17, 2022; the company sought an additional period and proposed seeking stockholder authorization for a reverse split. Regaining compliance was not assured.
- Disclosure controls were reported ineffective because of material weaknesses involving lack of segregation of duties and insufficient formal documentation of the control environment. Management described additional review procedures and plans to add experienced personnel, retain consultants, and upgrade its accounting system when feasible.
- WPD, a related party, had not paid the final invoice for Berubicin drug product delivered for its trials. The company reported receiving $393,182 of the amounts due but recorded no receivable for the unpaid final invoice because of collectability concerns. The filing says it was working to resolve the matter.
Most important facts for investors to verify
- Current cash runway, financing availability, and the actual funding required to complete the Berubicin trial and advance WP1244/WP1874.
- Berubicin trial enrollment, interim-analysis plans, costs, and clinical results, as well as the timing and scope of any regulatory interactions.
- Nasdaq bid-price compliance status and whether stockholders authorized a reverse split.
- Collection or resolution of WPD’s unpaid invoice and the implications of related-party arrangements.
- Progress in remediating the disclosed internal-control weaknesses and the potential dilution from outstanding warrants, options, and equity financing.